Spots Global Cancer Trial Database for tki258
Every month we try and update this database with for tki258 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Dose Escalating Study of TKI258 | NCT01471548 | Advanced Solid ... | TKI258 | 20 Years - | Novartis | |
| TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | NCT00243763 | Multiple Myelom... | TKI258 | 18 Years - | Novartis | |
| Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer | NCT00958971 | Metastatic Brea... | TKI258 | 18 Years - | Novartis | |
| Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors | NCT01155713 | Neoplasm Cancer Tumors | TKI258 | 18 Years - | Novartis | |
| TKI 258 in Von Hippel-Lindau Syndrome (VHL) | NCT01266070 | Von Hippel-Lind... | Dovitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies | NCT00669097 | Advanced Solid ... | TKI258 | 18 Years - | Novartis | |
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | NCT01831726 | Tumor Pathway A... | Dovitinib (TKI2... | 18 Years - 100 Years | Novartis | |
| A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | NCT01379534 | Solid Tumors an... Endometrial Can... Second-line Tre... VEGF | TKI258 | 18 Years - | Novartis | |
| TKI258 for Metastatic Inflammatory Breast Cancer Patients | NCT01262027 | Breast Cancer | Dovitinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| Phase II Study of TKI258 in Advanced Urothelial Carcinoma | NCT00790426 | Urothelial Canc... | TKI258 | 18 Years - | Novartis | |
| Safety of CHIR-258 (TKI258) in Advanced Solid Tumors | NCT01270906 | Neoplasms Cancer Tumors | CHIR-258 (TKI25... | 18 Years - | Novartis | |
| Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors | NCT01421004 | Advanced Solid ... Excluding Breas... | TKI258 | 18 Years - | Novartis | |
| Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors | NCT01421004 | Advanced Solid ... Excluding Breas... | TKI258 | 18 Years - | Novartis | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | NCT01379534 | Solid Tumors an... Endometrial Can... Second-line Tre... VEGF | TKI258 | 18 Years - | Novartis | |
| Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors | NCT01421004 | Advanced Solid ... Excluding Breas... | TKI258 | 18 Years - | Novartis | |
| A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | NCT01678105 | Recurrent Adeno... Metastatic Aden... Salivary Gland ... ACC | Dovitinib | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | NCT02720926 | Colorectal Canc... Gastric Cancer | Xeloda, Oxaliplatin TKI258 | 18 Years - | National Cancer Centre, Singapore | |
| TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | NCT00243763 | Multiple Myelom... | TKI258 | 18 Years - | Novartis | |
| Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | NCT00279773 | Acute Myeloid L... | TKI258 | 18 Years - | Novartis | |
| Phase I Dose Escalating Study of TKI258 | NCT01471548 | Advanced Solid ... | TKI258 | 20 Years - | Novartis | |
| Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | NCT00303251 | Melanoma | TKI258 | 18 Years - | Novartis | |
| Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors | NCT01596647 | Advanced Solid ... | caffeine diclofenac omeprazole midazolam TKI258 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
